Evaluation of Additive Neuroprotective Effect of Combination Therapy for Parkinson’s Disease Using In Vitro Models
We demonstrated that some of the medications, used in combination, can exert an additive neuroprotective effect in preclinical models of PD that is superior to that of each of the compounds individually. This project can lead to the development of the first treatment for PD that can slow or prevent its progression.
Authors
- Wolfgang Reintsch (ORCID: https://orcid.org/0000-0002-5466-7885)
- Andrea I. Krahn (ORCID: https://orcid.org/0000-0002-7975-6489)
- Thomas M. Durcan (ORCID: https://orcid.org/0000-0003-3942-1956)
- Florian Simon (ORCID: https://orcid.org/0000-0002-3731-3014)
- Joseph R. Mazzulli (ORCID: https://orcid.org/0000-0002-7692-2381)
- Alexander Shtilbans (ORCID: https://orcid.org/0000-0002-3159-8637)
- Elise Esneault
- Drew J. Quiriconi
- D. Rom
Institutions
- Northwestern University (US)
- Hospital for Special Surgery (US)
- Montreal Neurological Institute and Hospital (CA)
- Cornell University (US)
- Porsolt (France) (FR)
- Weill Cornell Medicine (US)
- McGill University (CA)
Publication Details
- Journal
- Antioxidants
- Published
- 2025-03-27
- DOI
- https://doi.org/10.3390/antiox14040396
- Citations
- 2
- Primary Topic
- Nuclear Receptors and Signaling
- Type
- article
- Field-Weighted Citation Impact
- 1.82